HIV Articles
Back
	Islatravir Metabolic, Kidney, Lipids       Islatravir Metabolic Outcomes in a Phase 2b Trial of Treatment-Naïve Adults with HIV-1 - (03/09/20)   Renal safety parameters of doravirine/islatravir (100/0.75 mg) vs bictegravir/emtricitabine/tenofovir alafenamide once-daily as initial HIV-1 treatment: week 48 results from a randomized, double-blind phase 3 trial   Week 96 Metabolic and Bone Outcomes of a Phase 2b Trial of Islatravir and Doravirine   Islatravir Safety Through 48 Weeks With Doravirine in Phase 2 Trial   Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes             View Older Articles   Back to Top   www.natap.org